2026 ACC Expert Consensus Decision Pathway on Heart Failure with Preserved Ejection Fraction

In what settings should you use the H₂FPEF, HFA-PEFF, and HFpEF-ABA scores in the diagnosis of HFpEF? What are HFpEF mimics? What is the difference between OMT and GDMT? Why is finerenone now preferred over spironolactone as the mineralocorticoid antagonist of choice in HFpEF? In which HFpEF patients should semaglutide or tirzepatide be prescribed? Why should ACE inhibitors be avoided in HFpEF, and which RAAS agents are actually supported by evidence? In which specific subgroups of HFpEF patients should sacubitril/valsartan be considered? Should HFpEF patients be given beta blockade? Which diabetes medications should be avoided in HFpEF patients, and which should replace them? How does the cardiovascular-kidney-metabolic framework help prioritize therapies with overlapping benefits across heart failure, diabetes, CKD, and obesity? Watch for answers to these key questions and more in this deep dive of the 2026 ACC Expert Consensus Decision Pathway on the Management of Heart Failure with Preserved Ejection Fraction. Watch on YouTube: https://youtu.be/HazAsFCjiAI Difficulty Level: Medium You are listening to Hu Said: Guideline Lifeline Please subscribe, rate, and support the channel! Ads help keep materials free for everyone. More MedEd resources available at ⁠⁠⁠⁠⁠www.rueyhu.com⁠⁠⁠⁠⁠ Updates at Twitter/X: ⁠⁠⁠⁠⁠@Ruey_Hu⁠